Possibilities today...Treatments Tomorrow

SEPTEMBER/OCTOBER 2026

Greetings and welcome to our early fall 2026 newsletter!

Fall is just around the corner offering a fresh chance to refocus our goals, assess new options, and reset after the summer break, especially when it comes to personal health.

Here at NorCal, we are really excited about the increasing clinical study options we can provide the community. Our growing clinical study portfolio will allow expanded opportunities to participate in clinical trials using the latest medications in development for overweight conditions that affect cardiometabolic health both for persons with and without type 2 diabetes. The goals in the studies for individuals without diabetes are prevention of diabetes and heart disease. The goals in our studies for patients with diabetes are to reduce complications and improve diabetes management!!!!

This newsletter highlights our two current clinical trials for persons without diabetes who are navigating overweight and obesity conditions and our two upcoming clinical trials for both persons with and without diabetes. See below for more details!

In just a few short years, GLP-1’s have completely reshaped the weight loss conversation, with data demonstrating that weight loss using the GLP-1's significantly reduces cardiovascular disease, sleep disorders, diabetes and a host of other health problems, including back, hip and knee pain.

Researchers continue to develop and test new medications in this class, combinations of medications, and have created new options and expanded dose options for oral as well as injectable medications. The goal of drug development is always grounded in safety and efficacy. The new preparations act similarly to the groundbreaking GLP-1’s but the emerging medications target multiple hormone receptors that work in different parts of the brain and gastrointestinal tract.

We are studying some of these promising new therapies, including long-acting amylin preparations and retatrutide, an investigational triple GLP-1/GIP/glucagon RA that has achieved up to 30% weight loss in latest trials with excellent tolerability.

These studies offer new options for individuals with overweight or obesity, with or without diabetes, who cannot tolerate, access, or may not have responded adequately to current GLP-1 medications.

See below or call us now for more information or to reserve your spot if you are interested in any of these studies, in losing weight and improving your health. Let your friends, patients and family know about our work.

Remember, new this year, NorCal continues to provide METABOLIC SCREENING including free finger stick HA1C and blood sugar testing. Anyone can take advantage of this free simple screening!!! Call to schedule.

Clinical trials are the cornerstone of evidence-based medicine, ensuring that every approved prescription is safe and effective, and warning about possible side effects. Beyond advancing healthcare for the broader public, trials give participants closely monitored, early access to promising new therapies in a safe environment. We are deeply grateful to our patients, whose participation makes these vital medical breakthroughs possible.

Best in health,

Dr. G

Linda Gaudiani MD FACE FACP

NORCAL Medical Director and Principal Investigator

CURRENT STUDIES

WEIGHT LOSS STUDY FOR PERSONS WITHOUT DIABETES

This Lilly study will investigate weight management with medications Macupatide and Eloralintide, alone or in combination, in adult participants with obesity or overweight and without diabetes.

You may be eligible if you:

are 18 to 75 years
have clinical obesity (if your body mass index is high, BMI of ≥30 kg/m2), or
have moderate overweight condition with risk factors (BMI ≥27 kg/m2) ) with at least one weight-related diagnosis (such as hypertension, high cholesterol or triglycerides, cardiovascular disease, obstructive sleep apnea, hyperuricemia/gout, PCOS, urinary incontinence, osteoarthritis, chronic lower back pain/knee pain, metabolic liver disease (MASLD) or “fatty liver,” or chronic kidney disease)
have an HbA1c of under 6.5% (that is you don’t have diabetes)
have not taken weight loss medications in the past 6 months.

Please call 415-461-1585 if you are interested.

NEW WEIGHT LOSS AMYLIN STUDY FOR PERSONS WITHOUT DIABETES

This AbbVie study will investigate a weight loss medication, (long-acting Amylin) in persons without diabetes.

Key Eligibility Criteria:

Inclusion Criteria:

• Individuals 18 to 75

• BMI ≥ 30.0 kg/m2 at Screening or

• BMI ≥ 27.0 to < 30.0 kg/m2 with at least one of the following weight-related conditions: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or MASLD.

Exclusion Criteria:

• Hemoglobin A1c (HbA1c) ≥ 6.5% (48 mmol/mol) at screening

• Fasting glucose ≥126 mg/dL or random glucose test ≥ 200 mg/dL

• History of type 1 or type 2 diabetes mellitus

• Treatment with any medication or product used for obesity or weight management within 180 days prior to screening.

Starting in September, call now! 415-461-1585

UPCOMING STUDIES

NEW ORAL WEIGHT LOSS RETATRUTIDE STUDY FOR PERSONS WITHOUT DIABETES

This Lilly study will investigate weight management with retatrutide, an oral triple hormone receptor agonist that activates the body's receptors for GLP-1, GIP and glucagon.

You may be eligible if you meet the following criteria (please call if you are not sure you can meet these criteria so we can help):

are 18 to 75 years
have clinical obesity condition (that is if your body mass index is high, BMI of ≥30 kg/m2 - we will calculate for you)
have moderate overweight condition (BMI ≥27 kg/m2) with at least one weight-related diagnosis (such as hypertension, high cholesterol or triglycerides, cardiovascular disease, obstructive sleep apnea, hyperuricemia/gout, PCOS, urinary incontinence, osteoarthritis, chronic lower back pain/knee pain, metabolic liver disease (MASLD) or “fatty liver,” or chronic kidney disease)
have an HbA1c of under 6.5% (that is you don’t have diabetes)
have not taken weight loss medications in the past 6 months

SCREENING NOW, so call us at 415-461-1585.

NEW WEIGHT LOSS PETRELINTIDE STUDY FOR PERSONS WITH T2 DIABETES

This study will investigate petrelintide, a long-acting amylin analog, for persons with type 2 diabetes.

You may be eligible if you meet the following criteria:

age 40 or older
BMI greater than 27.0 kg/m2 with diagnosis of T2D according to WHO classification or other locally applicable standards
HbA1c of 6.5% to 10% by central laboratory test at screening
stable treatment with either diet and exercise alone, basal insulin, or any oral glucose-lowering agent (except a GLP-1 receptor agonist)
no prior treatment with any GLP-1 receptor agonist, GLP-1/GIP receptor agonist (or any other GLP-1 based treatment) within 180 days prior to or during screening.

We expect a start date in October and are taking SCREENING INFO NOW for interested participants. Call us at 415-461-1585.

NORCAL KNOWLEDGE NUGGETS

ALL YOU NEED TO KNOW ABOUT RETATRUTIDE

Retatrutide is an investigational triple hormone receptor agonist that has produced some of the most dramatic weight loss results researchers have seen from any obesity medication to date. It has also delivered excellent results in patients with diabetes management, helping patients reach standard A1c targets and also lowering triglycerides and non-HDL cholesterol.

As mentioned above, in our retatrutide study we will be using an oral preparation in persons without diabetes!

HOW DOES IT WORK?

Semaglutide (Ozempic, Wegovy) targets GLP-1 receptors to promote fullness and lower blood sugar. Tirzepatide (Mounjaro, Zepbound) adds GIP targeting to boost insulin secretion and augment GLP-1 effects. Retatrutide targets three receptors—GLP-1, GIP, and glucagon—further enhancing appetite suppression and energy expenditure.

WHAT HAVE THE RESULTS BEEN IN CLINICAL TRIALS?

In Eli Lilly's 80-week TRIUMPH-1 phase 3 trial, retatrutide produced significant weight loss in non-diabetic adults with obesity or overweight and related condititons compared to placebo (2.2% loss):

12 mg: 28.3% average weight loss (~70 lbs), with 45.3% losing >30%
9 mg: ~26% average weight loss (~64 lbs)
4 mg: 19% average weight loss (~47 lbs)

Side effects observed so far have been very comparable to those of the entire GLP family, and include nausea, constipation, slower digestion, and fatigue, especially during dose increases. Doses can be adjusted for patients who need to lose lesser amounts of weight.

WHERE CAN YOU GET RETATRUTIDE TODAY?

Retatrutide is not yet FDA-approved and can only be obtained legitimately via clinical trials or manufacturer expanded access.

Unlike semaglutide or tirzepatide during shortages, compounding retatrutide is illegal under federal law. “Compounded” products lack quality control, accurate dosing, and purity standards and users face severe health risks by injecting unvetted substances without medical screening or supervision.

RETATRUTIDE EXPANDED ACCESS

In very special circumstances Eli Lilly offers Expanded Access to authentic retatrutide before FDA approval for select high risk patients who cannot join clinical trials. You can speak to your doctor about this opportunity if you:

are18 or older
have obesity unresponsive to maximum tolerated doses of existing approved medications
have at least two serious or life-threatening obesity-related conditions actively under medical care
are not eligible for ongoing approved retatrutide or similar clinical trials such as NorCal is conducting

If you are interested in taking Lilly's authentic retatrutide now, NORCAL is participating in a clinical trial and offers you the opportunity to do so safely.

Call us now to discuss your eligibility in the trial. 415-461-1585.

FREE SCREENING FOR METABOLIC RISKS AND DISEASES

Concerned about your risk of prediabetes or diabetes? FREE SCREENING can provide valuable information. “KNOWLEDGE IS POWER!!!”

In just a few minutes, we can conduct rapid on-site screening tests which we would be happy to send to your doctor upon request. No fasting necessary.

Fingerstick HA1C test
Fingerstick blood sugar test
BMI (Body Mass Index) assessment

Call Jesse or Carol for info on these studies or to make a convenient appointment at 415-461-1585.

Contact us at (415) 461-1585 or Info@NorCalMedicalResearch.com with any questions or feedback and please share this newsletter with anyone you think might benefit from receiving it and finding out about our work.

If you or someone you know would like to receive this newsletter IN SPANISH, please reach out to Info@NorCalMedicalResearch.com or call our office.

Thank you for being a subscriber.

Please forward and share this newsletter with friends and family.

Did you receive it from a friend? Click HERE to subscribe and find us in your inbox every month.

Read past editions of the newsletter HERE.

JOIN OUR MAILING LIST